278 related articles for article (PubMed ID: 24865476)
1. Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
Fred RG; Boddeti SK; Lundberg M; Welsh N
Clin Sci (Lond); 2015 Jan; 128(1):17-28. PubMed ID: 24865476
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
4. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
5. PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL.
Getachew R; Ballinger ML; Burch ML; Reid JJ; Khachigian LM; Wight TN; Little PJ; Osman N
Endocrinology; 2010 Sep; 151(9):4356-67. PubMed ID: 20610572
[TBL] [Abstract][Full Text] [Related]
6. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5'-phosphatase interaction with c-Abl.
Mokhtari D; Al-Amin A; Turpaev K; Li T; Idevall-Hagren O; Li J; Wuttke A; Fred RG; Ravassard P; Scharfmann R; Tengholm A; Welsh N
Diabetologia; 2013 Jun; 56(6):1327-38. PubMed ID: 23462796
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
9. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
10. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells.
Biswas SK; Zhao Y; Sandirasegarane L
Mol Vis; 2009 Aug; 15():1599-610. PubMed ID: 19693287
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
12. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
13. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Lupino E; Ramondetti C; Buccinnà B; Piccinini M
Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
[TBL] [Abstract][Full Text] [Related]
14. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
[TBL] [Abstract][Full Text] [Related]
15. c-Src couples PI 3 kinase/Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells.
Choudhury GG; Mahimainathan L; Das F; Venkatesan B; Ghosh-Choudhury N
Cell Signal; 2006 Nov; 18(11):1854-64. PubMed ID: 16530387
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
19. LRP: role in vascular wall integrity and protection from atherosclerosis.
Boucher P; Gotthardt M; Li WP; Anderson RG; Herz J
Science; 2003 Apr; 300(5617):329-32. PubMed ID: 12690199
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]